Article Details

Xtandi raise, Padcev lift and a women's health surprise: Astellas outlines $17B 5-year plan

Retrieved on: 2021-05-26 15:56:15

Tags for this article:

Click the tags to see associated articles and topics

Xtandi raise, Padcev lift and a women's health surprise: Astellas outlines $17B 5-year plan. View article details on hiswai:

Excerpt

To Barker's surprise, though, Astellas also raised peak sales estimates for investigational women's health drug fezolinetant to around JPY 300 billion ...

Article found on: www.fiercepharma.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up